Brazil will pilot Ozempic-style weight-loss drugs in its public health system, a demand signal for Novo Nordisk and Eli Lilly once prices fall.
Health Policy · Brazil
Key Facts
—The plan. Brazil’s health ministry will run a pilot to test offering Ozempic-style drugs through its public health system.
—The trial. It covers two hundred and fifty patients with severe obesity and heart complications, run at a hospital in Porto Alegre.
—The blocker. A government advisory body rejected these drugs for public use in 2025, citing a cost above eight billion reais.
BRAZIL · ECONOMY Key Facts —The approval: Brazil's health regulator cleared Ozivy, the country's first home-grown version of…
A Mounjaro price cut in Brazil, days before a cheaper local pen arrives, has touched off a price war in the country's…
A Brazilian drugmaker filed to launch its own version of the blockbuster weight-loss and diabetes drug, taking aim at a market…
Firm Novo Nordisk’s global patent is set to expire in parts of the world from early 2026, allowing cut-price ‘own-label’ versions…
Sales of weight-loss drugs in Brazil are reshaping pharmacy chains, now near a tenth of revenue, as a cheaper home-made version…
Following a shocking investigation into South Africa's unregulated beauty economy, authorities are cracking down on the dangerous…
